According to a clinical trial, both Solifenacin and posterior tibial nerve stimulation (PTNS) for overactive bladders lessened the severity of urine symptoms (such as urinary incontinence) and enhanced the quality of life for people with multiple sclerosis. Nastaran Majdinasab et al. compared the effects of Solifenacin and PTNS in 70 multiple sclerosis patients having an overactive bladder.

A total of two groups, each with 35 patients, were formed from volunteers with a score of a minimum of 3 as per the overactive bladder questionnaire. Patients were treated with Solifenacin (5 mg per day for 4 weeks and 10 mg/day for additional 8 weeks) in one group and with PTNS (12 weekly sessions, 30 minutes) in the other group.

The mean (standard deviation [SD]) age of the study's participants was 39.82 (9.088) years for the Solifenacin group and 42.41 (9.175) years for the PTNS group. Daytime frequency, micturition, and urinary incontinence significantly improved in patients in both groups. After 12 weeks, people in the Solifenacin group responded to treatment for urine incontinence more favourably than those in the PTNS group.

Additionally, contrasted with the PTNS group, subjects in the Solifenacin group reported greater satisfaction and decreased daytime frequency. Solifenacin and PTNS were valuable for treating the symptoms of overactive bladder in multiple sclerosis patients. However, in terms of treatment satisfaction rate, urine incontinence, and daytime frequency, patients showed that Solifenacin yielded a better experience.